Benjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CFO Benjamin Hohl sold 3,250 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $16.18, for a total value of $52,585.00. Following the completion of the transaction, the chief financial officer now owns 23,000 shares in the company, valued at approximately $372,140. This trade represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, April 28th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.69, for a total value of $60,742.50.
• On Thursday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $21.33, for a total value of $69,322.50.
• On Monday, March 24th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.50, for a total value of $22,500.00.

Enliven Therapeutics Trading Up 0.6%

NASDAQ ELVN traded up $0.10 on Friday, hitting $17.84. 290,192 shares of the company traded hands, compared to its average volume of 261,996. The company has a market capitalization of $875.39 million, a price-to-earnings ratio of -9.39 and a beta of 1.07. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03. The business's 50 day moving average price is $18.01 and its 200-day moving average price is $20.93.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Large investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its stake in Enliven Therapeutics by 2.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock valued at $5,892,000 after purchasing an additional 6,611 shares during the period. Wellington Management Group LLP lifted its holdings in Enliven Therapeutics by 15.3% in the 4th quarter. Wellington Management Group LLP now owns 80,916 shares of the company's stock worth $1,821,000 after purchasing an additional 10,746 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Enliven Therapeutics by 2.9% in the 4th quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock worth $44,452,000 after purchasing an additional 55,283 shares in the last quarter. Invesco Ltd. lifted its holdings in Enliven Therapeutics by 3.5% in the 4th quarter. Invesco Ltd. now owns 15,072 shares of the company's stock worth $339,000 after purchasing an additional 508 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in Enliven Therapeutics in the 4th quarter worth approximately $97,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Jones Trading dropped their price target on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research note on Friday, May 16th. HC Wainwright lifted their target price on Enliven Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, May 15th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Enliven Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $37.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.